In the PET trial, RAP-219 achieved and exceeded target receptor occupancy, increasing support for the dosing regimen utilized in the ongoing Phase 2a trial in focal epilepsy; restricted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback